Other ongoing studies, like KEYNOTE‐789, Checkmate‐722, ORIENT‐3, and TREASURE, are also investigating the therapeutic effects of immunotherapy plus chemotherapy and antiangiogenesis in EGFR mutation‐positive advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.